8/13/2020  1:29:11 PM Chg. +1.15 Volume Bid7:54:33 PM Ask7:54:33 PM Market Capitalization Dividend Y. P/E Ratio
202.70EUR +0.57% 0
Turnover: 0.00
203.80Bid Size: 500 204.05Ask Size: 500 119.5 bill.EUR - -

Business description

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
 

Management board & Supervisory board

CEO
Robert Bradway
Management board
Peter H. Griffith, Annalisa Pizzarello, Arleen Paulino, Corinne M. Le Goff, Cynthia M. Patton, Darryl Sleep, David A. Piacquad, David M. Reese, Elliot M. Levy, Esteban Santos, Gilles Marrache, Ian Thompson, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mike Nohaile, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Raymond Deshaies, Rob Lenz, Steven K. Galson, Susan Sweeney, Tia Bush, Victoria H. Blatter
Supervisory board
Robert A. Bradway, Amy E. Miles, Brian J. Druker, Charles M. Holley Jr., Ellen J. Kullman, Fred Hassan, Greg C. Garland, R. Sanders Williams, Robert A. Eckert, Ronald D. Sugar, Tyler Jacks, Wanda M. Austin
 

Company data

Name: Amgen Inc.
Address: One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA
Phone: +1-805-447-1000
Fax: +1-805-447-1010
E-mail: investor.relations@amgen.com
Internet: www.amgen.com
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 77.90%
IPO date: 6/17/1983

Investor relations

Name: -
IR phone: +1-805-447-1060
IR Fax: -
IR e-mail: -

Company calendar

CW 37 | 9/8/2020 Dividend Payment
 

Main Shareholders

Freefloat
 
77.90%
The Vanguard Group, Inc.
 
8.20%
BlackRock, Inc.
 
7.90%
Capital Research Global Investors
 
6.00%